Infinity Pharmaceuticals, Inc.
INFIDelisted- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001113148
Infinity Pharmaceuticals, Inc. was delisted in 2023; its insiders filed their last Form 4 on Sep 12, 2023; 45 institutions reported holding it in 13F filings for Q2 2023, worth $4.23M in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Infinity Pharmaceuticals, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Infinity Pharmaceuticals, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Perkins Adelene Q | Director | 1,175,291 | Sep 12, 2023 | 0 |
| Peluso Stephane | Chief Scientific Officer | 37,052 | Aug 4, 2022 | 0 |
| Beier David W | Director | – | Jun 16, 2022 | 0 |
| Selby Norman C | Director | – | Jun 16, 2022 | 0 |
| Evnin Anthony B | Director | 215,403 | Jun 16, 2022 | 0 |
| Schwartz Brian | Director | 30,919 | Jun 16, 2022 | 0 |
| Gaynor Richard | Director | – | Jun 16, 2022 | 0 |
| Agresta Samuel | Director | – | Jun 16, 2022 | 0 |
| Kango Sujay | Director | – | Mar 31, 2022 | 0 |
| Bloch Lawrence E | President | – | Jan 12, 2022 | 0 |
| Tasker Seth A | Chief Business Officer | – | Jan 12, 2022 | 0 |
| Ilaria Robert Jr. | Chief Medical Officer | – | Jan 12, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 12, 2023 (view filing)6:20 PM ET | Sep 12 | Same day | Perkins Adelene QDirector | SSale | −410.2K | $0.07 | −$28.7K | −25.9%1.18M after | 10b5-1 |
| Aug 4, 2022 (view filing) | Aug 2 | 2 days | Peluso StephaneChief Scientific Officer | SSale | +15.0K | $0.66 | +$9.90K | +68.0%37.1K after |